These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19299362)

  • 1. New gout treatment approved.
    Traynor K
    Am J Health Syst Pharm; 2009 Apr; 66(7):606. PubMed ID: 19299362
    [No Abstract]   [Full Text] [Related]  

  • 2. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 3. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 4. Gout management: let's get it right this time.
    Sundy JS
    Arthritis Rheum; 2008 Nov; 59(11):1535-7. PubMed ID: 18975368
    [No Abstract]   [Full Text] [Related]  

  • 5. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 7. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat : a viewpoint by Naomi Schlesinger.
    Schlesinger N
    Drugs; 2008; 68(13):1875-6. PubMed ID: 18729539
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat.
    Pascual E; Sivera F; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Mar; 8(3):191-2. PubMed ID: 19247302
    [No Abstract]   [Full Text] [Related]  

  • 11. Gout therapeutics: new drugs for an old disease.
    Burns CM; Wortmann RL
    Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
    Schumacher HR; Chen LX
    Drugs; 2008; 68(13):1875-6. PubMed ID: 18729538
    [No Abstract]   [Full Text] [Related]  

  • 13. Febuxostat : a viewpoint by N. Lawrence Edwards.
    Edwards NL
    Drugs; 2008; 68(13):1875-6. PubMed ID: 18729540
    [No Abstract]   [Full Text] [Related]  

  • 14. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M; Reid G
    J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
    Borghi C; Narkiewicz K; Mancia G
    Cardiol J; 2019; 26(1):99-101. PubMed ID: 30882192
    [No Abstract]   [Full Text] [Related]  

  • 16. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat for the treatment of gout.
    Bridgeman MB; Chavez B
    Expert Opin Pharmacother; 2015 Feb; 16(3):395-8. PubMed ID: 25556668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febuxostat for treatment of chronic gout.
    Gray CL; Walters-Smith NE
    Am J Health Syst Pharm; 2011 Mar; 68(5):389-98. PubMed ID: 21330679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.